サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1237027

全身性エリテマトーデス治療薬の市場：薬物クラス（抗マラリア薬、非ステロイド性抗炎症薬、細胞障害性・免疫抑制薬、生物製剤、その他）、デリバリー様式、地域別2023-2028

Systemic Lupus Erythematosus Drugs Market by Drug Class (Antimalarials Drugs, Non-Steroidal Anti-Inflammatory Drugs, Cytotoxic and Immunosuppressive Drugs, Biologics, and Others), Mode of Delivery, and Region 2023-2028
出版日: | 発行: IMARC | ページ情報: 英文 142 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.25円
全身性エリテマトーデス治療薬の市場：薬物クラス（抗マラリア薬、非ステロイド性抗炎症薬、細胞障害性・免疫抑制薬、生物製剤、その他）、デリバリー様式、地域別2023-2028
出版日: 2023年02月21日
発行: IMARC
ページ情報: 英文 142 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

全身性エリテマトーデス（SLE）治療薬の世界市場規模は、2022年に25億米ドルに達しました。今後、IMARC Groupは、2023年から2028年にかけて6.7%の成長率（CAGR）を示し、2028年までに38億米ドルに達すると予測しています。SLEに苦しむ患者数の増加、一般市民の意識向上キャンペーン、ジェネリック医薬品の容易な入手が、市場を牽引する主要因とされています。

全身性エリテマトーデス（SLE）は、自己免疫疾患であり、様々な臨床症状、多系統炎症（MIS）、再発寛解型経過（RRMS）を特徴とします。皮膚、関節、腎臓、脳など、身体の多くの部位に影響を及ぼします。一般的には、様々な遺伝的、環境的、ホルモン的要因によって引き起こされます。症状は、疲労、関節痛や腫れ、頭痛、発疹、脱毛、貧血、血液凝固、発熱などです。SLEは、症状評価、身体検査、胸部X線検査、尿検査、血液検査などを行い、ヘルスケアプロバイダーによって診断されます。その症状は、関節の痛みやこわばりには抗炎症剤、発疹にはステロイドクリーム、免疫反応を最小限に抑える副腎皮質ホルモン、皮膚のトラブルには抗マラリア薬を使って緩和することができます。また、より重症の場合は、疾患修飾薬や標的免疫系薬剤を使用します。このほか、免疫系の活動を抑制するさまざまな免疫抑制剤を用いて治療します。

全身性エリテマトーデス（SLE）治療薬の市場動向

  • 自己免疫疾患の有病率が高まり、SLEに罹患する患者数が増加していることが、世界中でSLE治療薬の需要を牽引する主要因の一つとなっています。さらに、多くの研究機関や診断機関が、SLEとその治療法について一般の人々を啓蒙するための対策やキャンペーンを実施しています。さらに、各国の政府や非政府組織（NGO）は、新規治療薬の開発やSLE治療に関連する創薬標的を特定するためのさまざまなプログラムに投資しています。このような背景のもと、ヘルスケアインフラや診断技術を向上させるための資金が世界的に増加し、市場の成長に拍車をかけています。これとは別に、SLEに伴う痛み、炎症、こわばりを緩和するさまざまなジェネリック医薬品が、オフラインやオンラインの小売チャネルで簡単に入手できることも、市場成長に好影響を与えています。一般に、アスピリン、イブプロフェン（Motrin）、ナプロキセン、セレコキシブ（Celebrex）、ジクロフェナク（Voltaren）、ジフルニサル（Dolobid）、ピロキシカム（Feldene）といった非ステロイド性抗炎症薬の市販薬（OTC）や処方薬が使われています。さらに、ヒドロキシクロロキン製剤の使用量が増加していることも、市場の成長に寄与しています。このほか、SLEの早期診断と治療の利点に関する個人やヘルスケア専門家の意識の高まりが、SLE治療薬の全体的な売上に影響を与えています。

主要市場のセグメンテーション

  • IMARC Groupは、世界の全身性エリテマトーデス（SLE）治療薬市場の各セグメントにおける主要動向の分析と、2023年から2028年までの世界、地域、国レベルでの予測を提供します。当レポートでは、薬剤クラスとドラッグデリバリー様式に基づき市場を分類しています。

本レポートで回答した主な質問

  • 世界の全身性エリテマトーデス（SLE）治療薬市場はこれまでどのように推移し、今後数年間はどのように推移するのでしょうか？
  • 世界の全身性エリテマトーデス（SLE）治療薬市場における市場促進要因、抑制要因、機会は何か？
  • 主要な地域市場とは？
  • 最も魅力的な全身性エリテマトーデス（SLE）治療薬市場はどの国か？
  • 薬剤クラスに基づく市場の内訳は？
  • 投与方法別の市場内訳は？
  • 全身性エリテマトーデス（SLE）治療薬の世界市場における競合構造は？
  • 世界の全身性エリテマトーデス（SLE）治療薬市場における主要企業は？

目次

第1章 序文

第2章 範囲と調査手法

  • 研究の目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場予測
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 予測調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要な業界動向

第5章 世界の全身性エリテマトーデス（SLE）薬市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 医薬品クラス別の市場内訳

  • 抗マラリア薬
    • 市場動向
    • 主要セグメント
      • クロロキン
      • ヒドロキシクロロキン
    • 市場予測
  • 非ステロイド系抗炎症薬（NSAIDS）
    • 市場動向
    • 市場予測
  • 細胞傷害性および免疫抑制薬
    • 市場動向
    • 主要セグメント
      • シクロホスファミド
      • メトトレキサート
      • ミコフェノール酸モフェチル
      • タクロリムス
      • シクロスポリン
    • 市場予測
  • 生物製剤
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第7章 配送モード別市場内訳

  • 静脈内
    • 市場動向
    • 市場予測
  • 皮下
    • 市場動向
    • 市場予測
  • オーラル
    • 市場動向
    • 市場予測

第8章 地域別の市場内訳

  • 北米
    • 米国
      • 市場動向
      • 市場予測
    • カナダ
      • 市場動向
      • 市場予測
  • アジア太平洋
    • 中国
      • 市場動向
      • 市場予測
    • 日本
      • 市場動向
      • 市場予測
    • インド
      • 市場動向
      • 市場予測
    • 韓国
      • 市場動向
      • 市場予測
    • オーストラリア
      • 市場動向
      • 市場予測
    • インドネシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場動向
      • 市場予測
    • フランス
      • 市場動向
      • 市場予測
    • 英国
      • 市場動向
      • 市場予測
    • イタリア
      • 市場動向
      • 市場予測
    • スペイン
      • 市場動向
      • 市場予測
    • ロシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場動向
      • 市場予測
    • メキシコ
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 中東とアフリカ
    • 市場動向
    • 国別の市場内訳
    • 市場予測

第9章 促進要因、制約、および機会

  • 概要
  • 促進要因
  • 抑制要因
  • 機会

第10章 バリューチェーン分析

第11章 ポーターズファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第12章 価格分析

第13章 競合情勢

  • 市場構造
  • 主なプレーヤー
  • 主なプレーヤーのプロファイル
    • AstraZeneca Plc
    • Aurinia Pharmaceuticals Inc.
    • GSK plc
    • ImmuPharma Plc

これは企業の部分的なリストを表しているに過ぎず、完全なリストはレポートで提供されています。

図表

List of Figures

  • Figure 1: Global: Systemic Lupus Erythematosus Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 4: Global: Systemic Lupus Erythematosus Drugs Market: Breakup by Drug Class (in %), 2022
  • Figure 5: Global: Systemic Lupus Erythematosus Drugs Market: Breakup by Mode of Delivery (in %), 2022
  • Figure 6: Global: Systemic Lupus Erythematosus Drugs Market: Breakup by Region (in %), 2022
  • Figure 7: Global: Systemic Lupus Erythematosus Drugs (Antimalarials Drugs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 8: Global: Systemic Lupus Erythematosus Drugs (Antimalarials Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 9: Global: Systemic Lupus Erythematosus Drugs (Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 10: Global: Systemic Lupus Erythematosus Drugs (Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 11: Global: Systemic Lupus Erythematosus Drugs (Cytotoxic and Immunosuppressive Drugs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 12: Global: Systemic Lupus Erythematosus Drugs (Cytotoxic and Immunosuppressive Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 13: Global: Systemic Lupus Erythematosus Drugs (Biologics) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 14: Global: Systemic Lupus Erythematosus Drugs (Biologics) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 15: Global: Systemic Lupus Erythematosus Drugs (Other Drug Classes) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 16: Global: Systemic Lupus Erythematosus Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 17: Global: Systemic Lupus Erythematosus Drugs (Intravenous) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 18: Global: Systemic Lupus Erythematosus Drugs (Intravenous) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 19: Global: Systemic Lupus Erythematosus Drugs (Subcutaneous) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 20: Global: Systemic Lupus Erythematosus Drugs (Subcutaneous) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 21: Global: Systemic Lupus Erythematosus Drugs (Oral) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 22: Global: Systemic Lupus Erythematosus Drugs (Oral) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 23: North America: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 24: North America: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 25: United States: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 26: United States: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 27: Canada: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 28: Canada: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 29: Asia-Pacific: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 30: Asia-Pacific: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 31: China: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 32: China: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 33: Japan: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 34: Japan: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 35: India: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 36: India: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 37: South Korea: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 38: South Korea: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 39: Australia: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 40: Australia: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 41: Indonesia: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 42: Indonesia: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 43: Others: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 44: Others: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 45: Europe: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 46: Europe: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 47: Germany: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 48: Germany: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 49: France: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 50: France: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 51: United Kingdom: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 52: United Kingdom: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 53: Italy: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 54: Italy: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 55: Spain: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 56: Spain: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 57: Russia: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 58: Russia: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 59: Others: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 60: Others: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 61: Latin America: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 62: Latin America: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 63: Brazil: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 64: Brazil: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 65: Mexico: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 66: Mexico: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 67: Others: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 68: Others: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 69: Middle East and Africa: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 70: Middle East and Africa: Systemic Lupus Erythematosus Drugs Market: Breakup by Country (in %), 2022
  • Figure 71: Middle East and Africa: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 72: Global: Systemic Lupus Erythematosus Drugs Industry: Drivers, Restraints, and Opportunities
  • Figure 73: Global: Systemic Lupus Erythematosus Drugs Industry: Value Chain Analysis
  • Figure 74: Global: Systemic Lupus Erythematosus Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Systemic Lupus Erythematosus Drugs Market: Key Industry Highlights, 2022 & 2028
  • Table 2: Global: Systemic Lupus Erythematosus Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2023-2028
  • Table 3: Global: Systemic Lupus Erythematosus Drugs Market Forecast: Breakup by Mode of Delivery (in Million US$), 2023-2028
  • Table 4: Global: Systemic Lupus Erythematosus Drugs Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 5: Global: Systemic Lupus Erythematosus Drugs Market: Competitive Structure
  • Table 6: Global: Systemic Lupus Erythematosus Drugs Market: Key Players
目次
Product Code: SR1523A292_Report

The global systemic lupus erythematosus (SLE) drugs market size reached US$ 2.5 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 3.8 Billion by 2028, exhibiting a growth rate (CAGR) of 6.7% during 2023-2028.The increasing number of patients suffering from SLE, rising public awareness campaigns, and the easy availability of generic drugs represent some of the key factors driving the market.

Systemic lupus erythematosus (SLE) is an autoimmune medical condition characterized by protean clinical manifestations, multisystem inflammation (MIS), and a relapsing and remitting course (RRMS). It affects numerous parts of the body, including the skin, joints, kidneys, and brain. It is generally caused due to various genetic, environmental, and hormonal factors. Its symptoms include fatigue, joint pain and swelling, headache, rashes, hair loss, anemia, blood clotting, and fever. SLE is diagnosed by a healthcare provider using symptom assessments, physical examinations, chest X-rays, urinalysis, and blood tests. Its symptoms can be eased using anti-inflammatory drugs for joint pain and stiffness, steroid creams for rashes, corticosteroids to minimize the immune response, and antimalarial drugs for skin problems. It also uses disease-modifying drugs and targeted immune system agents for more severe cases. Besides this, it is treated using various immunosuppressive drugs that inhibit the activity of the immune system.

Systemic Lupus Erythematosus (SLE) Drugs Market Trends:

  • The increasing prevalence of autoimmune diseases among individuals and the rising number of patients suffering from SLE represents one of the major factors driving the demand for SLE drugs around the world. Moreover, the rising number of research and diagnostics institutes are undertaking measures and introducing public awareness campaigns to educate individuals about SLE and its possible treatments. In addition, governments and non-governmental organizations (NGOs) of numerous countries are investing in various programs to develop novel therapeutics and identify relevant drug targets for the treatment of SLE. This, coupled with the increasing financing to improve healthcare infrastructure and diagnostic technologies worldwide, is impelling the market growth. Apart from this, the easy availability of various generic drugs for relieving pain, inflammation, and stiffness associated with SLE through offline and online retail channels is favoring the market growth. They generally involve over the counter (OTC) and prescription-based nonsteroidal anti-inflammatory drugs (NSAIDs), such as aspirin, ibuprofen (Motrin), naproxen, celecoxib (Celebrex), diclofenac (Voltaren), diflunisal (Dolobid), and piroxicam (Feldene). Furthermore, the increasing use of Hydroxychloroquine drugs is contributing to the market growth. Besides this, the growing awareness among individuals and healthcare professionals about the benefits of early diagnosis and treatment of SLE is influencing the overall sales of SLE drugs.

Key Market Segmentation:

  • IMARC Group provides an analysis of the key trends in each segment of the global systemic lupus erythematosus (SLE) drugs market, along with forecasts at the global, regional, and country level from 2023-2028. Our report has categorized the market based on drug class and mode of delivery.

Drug Class Insights:

  • Antimalarials Drugs
  • Chloroquine
  • Hydroxychloroquine
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
  • Cytotoxic and Immunosuppressive Drugs
  • Cyclophosphamide
  • Methotrexate
  • Mycophenolate Mofetil
  • Tacrolimus
  • Cyclosporine
  • Biologics
  • Others
  • The report has also provided a detailed breakup and analysis of the systemic lupus erythematosus (SLE) drugs market based on the drug class. This includes antimalarials drugs (chloroquine and hydroxycholroquine), non-steroidal anti-inflammatory drugs (NSAIDS), cytotoxic and immunosuppressive drugs (cyclophophamide, methotrexate, mycophenolate mofetil, tacrolimus, and cyclosporine), biologics, and others. According to the report, cytotoxic and immunosuppressive drugs represented the largest segment.

Mode of Delivery Insights:

  • Intravenous
  • Subcutaneous
  • Oral
  • A detailed breakup and analysis of the systemic lupus erythematosus (SLE) drugs market based on the mode of delivery has also been provided in the report. This includes intravenous, subcutaneous, and oral. According to the report, oral accounted for the largest market share.

Regional Insights:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa
  • The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and the Middle East and Africa. According to the report, North America was the largest market for systemic lupus erythematosus (SLE) drugs. Some of the factors driving the North America systemic lupus erythematosus (SLE) drugs market included easy access to healthcare, the rising awareness about the benefits of early diagnosis and treatment of SLE, and the easy availability of various generic drugs.

Competitive Landscape:

  • The report has also provided a comprehensive analysis of the competitive landscape in the global systemic lupus erythematosus (SLE) drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include AstraZeneca Plc, Aurinia Pharmaceuticals Inc., GSK plc, and ImmuPharma Plc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

  • How has the global systemic lupus erythematosus (SLE) drugs market performed so far and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global systemic lupus erythematosus (SLE) drugs market?
  • What are the key regional markets?
  • Which countries represent the most attractive systemic lupus erythematosus (SLE) drugs markets?
  • What is the breakup of the market based on the drug class?
  • What is the breakup of the market based on the mode of delivery?
  • What is the competitive structure of the global systemic lupus erythematosus (SLE) drugs market?
  • Who are the key players/companies in the global systemic lupus erythematosus (SLE) drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Systemic Lupus Erythematosus (SLE) Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Antimalarials Drugs
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Chloroquine
      • 6.1.2.2 Hydroxychloroquine
    • 6.1.3 Market Forecast
  • 6.2 Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Cytotoxic and Immunosuppressive Drugs
    • 6.3.1 Market Trends
    • 6.3.2 Key Segments
      • 6.3.2.1 Cyclophosphamide
      • 6.3.2.2 Methotrexate
      • 6.3.2.3 Mycophenolate Mofetil
      • 6.3.2.4 Tacrolimus
      • 6.3.2.5 Cyclosporine
    • 6.3.3 Market Forecast
  • 6.4 Biologics
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Mode of Delivery

  • 7.1 Intravenous
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Subcutaneous
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Oral
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia-Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 Drivers, Restraints, and Opportunities

  • 9.1 Overview
  • 9.2 Drivers
  • 9.3 Restraints
  • 9.4 Opportunities

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 AstraZeneca Plc
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 Aurinia Pharmaceuticals Inc.
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
    • 13.3.3 GSK plc
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 ImmuPharma Plc
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.